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Introduction
Hypertension is a growing public health con-
cern for which successful treatment often remains
elusive. In the United States, an estimated one in
three adults has hypertension and the global pre-
valence continues to climb, particularly in develo-
ping countries [1, 2]. Despite access to pharmacolo-
gical therapies and resources to help patients
achieve necessary lifestyle modifications, approxi-
mately half of patients fail to achieve recommended
target blood pressure values [1]. This can perhaps
be attributed to patient non-adherence as a result
of physician inertia, polypharmacy, adverse drug
events and patient resistance to a lifelong regimen
for a largely asymptomatic disease. More than
50 years of drug development has worked to the
benefit of many hypertensive patients. But such de-
velopment has slowed and the time has come to
consider non-drug therapies for this rampant dise-
ase. New therapeutic approaches that will overcome
these obstacles are essential [3, 4].
A small, but significant, percentage of patients
[5] with uncontrolled hypertension fail to meet thera-
peutic targets despite taking multiple drug thera-
pies at the highest tolerated doses, a phenomenon
called ‘resistant hypertension’. This may suggest
underlying pathophysiology resistant to current
pharmacological approaches [4]. Innovative thera-
peutic approaches are particularly relevant for these
patients, as their condition puts them at high risk
of major cardiovascular events [6].
Renal afferent and sympathetic efferent nerves
have been implicated in the pathophysiology of sys-
temic hypertension [7–10]. As a result, a  succes-
sion of therapeutic approaches have targeted the
sympathetic nervous system to modulate hyperten-
sion, with varying success. Many of these early
approaches involved radical sympathetic denerva-
tion, failing to target specific organs thought to be
directly involved with the pathophysiology of the
disease. While successful in reducing blood pres-
sure, the broad nature of these approaches led to
many perioperative and long-term complications,
including bowel, bladder and erectile dysfunction,
as well as the dreaded side-effect of postural hy-
potension [11–13].
But a more targeted approach of renal sympa-
thetic denervation remains a potential therapeutic
option and is emerging as a subject of active re-
search. Recent studies have aimed to assess the
safety and efficacy of a percutaneous, catheter-
-based approach designed to specifically ablate re-
nal sympathetic nerves using a radiofrequency gene-
rator via the lumen of the main renal artery. In
a safety and proof-of-principle study, and a separate
randomized controlled trial, both published in the
Lancet, in 2009 and 2010 respectively, this approach
was shown to successfully reduce blood-pressure,
without serious adverse events in patients with
resistant hypertension [3, 4]. This article will re-
view the recent literature regarding catheter-based
renal ablation in the context of current knowledge
of the pathophysiology of resistant hypertension,
and will explore future directions for research re-
garding this new approach.
Renal innervation and the
pathophysiology of hypertension
For the first half of the 20th century, renal in-
nervation was thought to extend only to the renal
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vasculature, and renal nerves were believed to have
little functional consequence [14]. The subsequent
demonstration that norepinephrine-containing re-
nal sympathetic nerve terminals make contact with
the renal tubular epithelial cell basement membrane
[15] opened a new line of questioning regarding
neural control of the kidney and its implications for
clinical medicine.
Renal sympathetic nerves were discovered to
stimulate neuroeffectors throughout the kidney,
with graded effects at progressively higher frequen-
cies of stimulation. At low frequencies, sympathe-
tic nerve activation of juxtaglomerular cells in-
creased renin secretion alone. With slightly higher
frequencies, effects expanded to include reduced
urinary sodium excretion via sympathetic nerve
activation of the renal tubular epithelial cells, es-
pecially those of the proximal tubule and the thick
ascending limb of Henle’s Loop. Finally, at high fre-
quency stimulation, renal vasoconstriction occurred
with corresponding decreased renal blood flow and
glomerular filtration rate via vascular smooth mus-
cle cell contraction of the resistance vessels and
preferential preglomerular vasoconstriction of the
microvessels, expanding upon the already increased
renin and reduced urinary sodium excretion. Thus,
the impact of renal innervation occurs long before
changes in renal hemodynamics can be seen (arte-
rial pressure, glomerular filtration rate and renal
blood flow) and, if renal sympathetic stimulation is
sufficient to cause changes in renal hemodynamics,
then it will also stimulate renin secretion and pro-
duce antinatriuresis (sodium retention) [14].
Such discoveries explained the observations of
hypertension in patients with increased renin se-
cretion and reduced urinary sodium excretion but
normal renal blood flow and elevated glomerular fil-
tration rate, using a new model: hypertension as
a result of elevated renal sympathetic activity be-
low the threshold that would affect renal hemody-
namics [14]. Early studies which demonstrated that
renal denervation could prevent, delay or marked-
ly attenuate experimental hypertension in a varie-
ty of animal models further reinforced this expla-
nation [8]. Thus, it was hypothesized that the etio-
logy of hypertension was a central nervous system
abnormality in the regulation of renal sympathetic
nervous activity inducible by increased dietary so-
dium intake and environmental stress occurring in
the proper genetic context [14].
It is now known that autonomic control of the
kidney is predominantly sympathetic, and media-
ted by a dense network of post-ganglionic sympa-
thetic neurons in the kidney [16, 17]. Hypertension
is characterized by excessive stimulation of this
sympathetic neural network, evidenced by high
rates of renal norepinephrine spillover into the cir-
culation, and increased systemic sympathetic nerve
firing, possibly modulated by afferent renal senso-
ry nerves [10, 18]. This excessive sympathetic out-
flow to the kidney increases both renin release and
tubular sodium reabsorption, and often reduces re-
nal blood flow [8, 9].
In addition, afferent signals from the kidney
directly contribute to neurogenic hypertension by
modulating central sympathetic outflow [19–21].
Afferent renal sympathetic nerves originate most-
ly from the renal pelvic wall and respond to either
mechanoreceptors that detect stretch, or chemore-
ceptors that detect renal ischemia [8, 21–24]. These
fibers, which have cell bodies in the ipsilateral dor-
sal root ganglia (T6–L4), ascend to the central ner-
vous system, mainly to the hypothalamus, where
they evoke functional changes and a central sym-
pathetic response [25–27].
Prior to the advent of effective antihyperten-
sive drugs, non-selective surgical sympathectomy,
often called ‘splanchnicectomy’, as it needed to in-
clude the abdominal viscera [5], was used to de-
nervate the kidney for the treatment of severe hy-
pertension, representing a direct interventional
application of this new model of hypertension [12,
28]. While the technique effectively improved sur-
vival in a population with a devastating mortality
rate of almost 100% in five years [5, 29], it was as-
sociated with many debilitating side-effects such as
postural hypotension, orthostatic tachycardia, pal-
pitations, intestinal disturbances and erectile dys-
function, attributed to non-specific sympathetic
denervation of the viscera and lower extremity vas-
culature [5, 14].
It is also worth noting that, in addition to im-
proving blood pressure in about half of patients, it
also rendered blood pressure more sensitive to
antihypertensive drugs [29]. The use of newly de-
veloped endovascular catheter technology for se-
lective renal denervation is an innovative twist on
this old idea, taking advantage of its potential bene-
fits, while avoiding its historic downfalls.
Renal sympathetic denervation
In this newly developed approach, a catheter
connected to a radiofrequency generator (Symplici-
ty by Ardian Inc., Palo Alto, CA, USA) is introduced
percutaneously to the lumen of the main renal ar-
tery via femoral access and used to disrupt renal
nerves located in the adventitia of these arteries,
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without affecting other abdominal, pelvic, or lower
extremity innervations [3, 4]. This technique aims
to ablate efferent sympathetic and sensory afferent
fibers of the renal nerves, both of which are thought
to contribute to the blood pressure-lowering effect
of catheter-based renal denervation [30]. Preclini-
cal studies performed by Ardian Inc. in juvenile
swine reported the effectiveness of this technique
at achieving renal denervation without causing se-
vere vascular or renal injury up to six months fol-
lowing the procedure [3].
This technique has some significant advantages
over the radical sympathectomy performed prior to
the advent of anti-hypertensive drugs. These ad-
vantages potentially make it a viable therapeutic
option for patients with resistant hypertension and
for patients with other diseases thought to be as-
sociated with hyperactive renal sympathetic and
afferent activity, such as chronic kidney disease and
congestive heart failure. These advantages include
short procedural and recovery times, the use of
a minimally invasive approach and the localization
of the procedure to the kidney, thereby avoiding the
systemic side-effects that have plagued patients in
the past [5].
Early clinical results
An initial cohort study, performed by Krum et al.
[3], demonstrated the efficacy of this novel catheter-
-based device at producing both renal denervation
and corresponding, clinically and statistically signifi-
cant reductions in blood pressure over a 12 month
period (reductions of 14/10, 21/10, 22/11, 24/11, and
27/17 mm Hg at one, three, six, nine, and 12 months,
respectively), without serious adverse effects, in
a group of 45 patients who met specific clinical cri-
teria for resistant hypertension (blood pressures of
≥ 160 mm Hg, or ≥ 150 mm Hg for patients with
type 2 diabetes, despite compliance with three or
more antihypertensive drugs). Periprocedural ad-
verse events were limited to a pseudo-aneurysm at
the femoral access site and one renal artery dissec-
tion upon placement of the catheter prior to the de-
livery of radiofrequency energy in that artery, at
which point the procedure was aborted; both of these
instances were related to the percutaneous tech-
nique, rather than the radiofrequency ablation, and
were treated without subsequent, long-term compli-
cations over the 12 months following the procedure.
Aiming primarily to assess safety and proof-of-
-principle, Krum’s study [3] had a relatively small
sample size, lacked a proper control group (unrando-
mized and not placebo-controlled), did not restrict
medication adjustment or maintain strict recruit-
ment criteria, and failed to exclude secondary forms
of resistant hypertension. These faults limit the
extent to which these results can be applied to the
clinical management of hypertension and associa-
ted disorders. In spite of these limitations, the study
supports the potential of this approach to effective-
ly and persistently reduce blood pressure without
long-term complications in populations with resis-
tant hypertension and the resultant need for further
study of this novel procedure.
It is also of note that, in the 12 month follow-
-up period, the blood-pressure lowering results did
not attenuate, indicating that the ablated nerve fi-
bers did not recover or regrow, and that compen-
satory, blood pressure-restoring mechanisms did
not develop throughout the duration of the follow-
-up period. These results speak to the potential of
the procedure to have a persistent antihypertensive
effect [3]. The regrowth of renal sympathetic effer-
ent nerves in kidney and heart transplant models
have raised concerns regarding the maintenance of
blood pressure-lowering effects over the long term.
However, the functional significance of this re-
growth is not yet known and will require explora-
tion in future studies. In contrast, the afferent sen-
sory fibers of the renal nerves are not known to have
this regenerative potential [31] and are likely to play
an important role in the blood pressure-reducing
effect of renal denervation, as evidenced by the sig-
nificant decrease in central sympathetic drive as-
sociated with this technique (measured indirectly
as a reduction in whole-body norepinephrine spill-
over) [30].
Building upon this work, the Symplicity HTN-2
investigators (Esler et al. [4]) performed a random-
ized controlled trial (Symplicity HTN-2 Trial) to
study the effectiveness and safety of catheter-based
renal denervation with the Symplicity Catheter Sys-
tem (Ardian, Mountain View, CA, USA) to reduce
blood pressure in a similar, but larger, population
of patients with resistant hypertension, defined
using the same criteria as the previous study by
Krum et al. [3]. This study of 106 patients, each ran-
domly allocated either to undergo renal denervation
with previous treatment, or to maintain previous
treatment alone (control), found a 33/11 mm Hg re-
duction in office-based blood pressure in the renal
denervation group compared to the control group
at six month follow-up (p < 0.0001 for systolic and
diastolic blood pressure). These changes were par-
alleled by similar reductions in: (1) home-based
blood pressure measurements; (2) average blood
pressure measurements derived from 24-h ambu-
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latory blood pressure recordings; and (3) the need
for anti-hypertensive drugs. Of the patients ana-
lyzed, ten (four who underwent renal denervation
and six from the control group) had drug increases
prior to the follow-up. In a sub-analysis that cen-
sored data from these patients following their drug
increases, there was an absolute difference in blood
pressure reduction between the two groups of
31/11 mm Hg (p < 0.0001 for systolic and diastolic
blood pressure). The results of this important study
further support those from Krum’s proof-of-princi-
ple study regarding the effectiveness of catheter-
-based renal denervation at reducing blood pressure
in patients with resistant hypertension.
This randomized controlled trial also addressed
both acute and chronic procedural safety. Of the 52
patients who underwent renal ablation, 12 (23%)
experienced a peri-procedural event of some kind,
including seven incidences of transient intraproce-
dural bradycardia requiring atropine (none of which
had any sequelae in the six months to follow-up),
one femoral artery psuedoaneurysm, one post-pro-
cedural drop in blood pressure, one urinary tract
infection, one extended hospital admission for as-
sessment of parasthesias, and one case of back pain.
With respect to chronic procedural safety, there was
no statistically significant difference in the change
in renal function at six months between the two
groups (assessed by serum creatinine, estimated
glomerular filtration rate, cystatin-C concentration
and albumin-to-creatinine ratio), nor were there any
instances of new stenosis (> 60% occlusion con-
firmed by angiogram) at the sites of radiofrequen-
cy delivery. Even so, there is some concern regard-
ing tissue damage and resulting structural changes
to the renal artery, as severe adverse events have
been observed in other instances in which radio-
frequency ablation has been utilized, such as atrial
fibrillation [32, 33]. The comparatively low frequen-
cy of energy used in this technique makes such
changes less likely. However, the long-term impact
on renal artery structure of this procedure remains
unclear [5].
The Symplicty HTN-2 investigators reported
five additional “serious adverse events” requiring
hospital admission in patients who underwent re-
nal denervation (compared to three controls with
such events); these included both hypotensive and
hypertensive episodes, as well as a transient is-
chemic attack, angina requiring a coronary stent,
and one episode of nausea and edema perhaps re-
lating to underlying hypertension [4].
Naturally, a risk of complications would be ex-
pected to accompany any invasive procedure, par-
ticularly in patient populations with significant un-
derlying morbidity, such as resistant hypertension.
This study plays an important role in elucidating at
least a portion of the risk associated with catheter-
-based renal ablation. However, the six month fol-
low-up time and relatively small sample size of this
study limit its ability to be generalized with respect
to safety and expected adverse events. Thus, it re-
mains to be determined what the risks of catheter-
-denervation are likely to entail and whether or not
such risks are acceptable in the context of the ex-
pected benefit of the procedure for the individual
patient. The durability of the effect will also be an
extremely important endpoint.
Other limitations of the recent literature in-
clude baseline differences between the control and
renal denervation groups, as well as bias related to
potential conflicts of interest. At baseline in the
initial randomized control trial [4], the renal dener-
vation group had a greater percentage of males
(65%, compared to 50% of controls), higher rates
of type 2 diabetes (40%, compared to 28% of con-
trols) and coronary artery disease (19%, compared
to 7% of controls), and more patients on five or more
medications at baseline (67%, compared to 50% of
controls), perhaps indicating more severe cases of
hypertension. This over-representation of co-mor-
bidities and severe cases among those who under-
went renal denervation may have skewed the re-
sults in the direction of greater blood pressure re-
duction than might have been seen in the general
population of patients with resistant hypertension
following catheter-based renal denervation. In the
same way, these differences may also have predis-
posed the renal denervation group to higher rates
of complications than might have been seen in the
control group.
Discussion
Preliminary clinical results suggest that cath-
eter-based renal denervation utilizing the Symplici-
ty catheter could be a feasible, effective and safe
therapeutic option for patients with resistant hyper-
tension. Still, there are many questions that must
be answered regarding the technique’s effective-
ness and safety before the acceptance of this ap-
proach in the clinical setting.
In-depth follow-up is essential to measure the
long-term impact of this technique. For instance,
the presence of nerve fiber regrowth and recovery,
particularly of efferent nerve fibers, as well as the
development of compensatory blood pressure-in-
creasing mechanisms, must be assessed over
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a longer time than the 12 months reported in
Krum’s proof-of-principle trial. In addition, long-
-term follow-up is required to measure cardiovas-
cular impact. The Symplicity HTN-2 Trial utilized
a composite cardiovascular endpoint, but assessed
it only at six month follow-up. In this short time,
five of the 100 subjects that were not lost to follow-
-up (three who underwent renal denervation and two
controls) were admitted to hospital, all for hyper-
tensive emergency. This endpoint would perhaps
be more significant over a longer period of time, and
could be extremely important in elucidating the
risks and benefits of the technique with respect to
cardiovascular disease. A longer follow-up period
in a larger population of patients is also required to
assess safety before the application of this tech-
nique in clinical practice. Such modifications would
allow for a more accurate assessment of the true
risks associated with the procedure.
In the Symplicity HTN-2 Trial, 84% of patients
achieved a ≥ 10 mm Hg decrease in systolic blood
pressure (compared with 35% of controls) and 39%
achieved a systolic blood pressure of less than 140
mm Hg at six months (compared with 6% of con-
trols) [4]. Thus, there is a clear range of respon-
siveness to this technique. Additionally, a small
percentage of patients experienced adverse events.
It is critical that those factors that put patients at
higher likelihood of benefit from this procedure, and
at higher risk of experiencing an adverse event, be
identified so that ideal candidates for the procedure
can be targeted and high risk candidates avoided.
The extent of ablation-induced afferent dener-
vation and the impact that this will have on blood
pressure and its sequelae still remains to be eluci-
dated. Periprocedural pain [4] and increased cen-
tral sympathetic outflow [30] suggest that there is,
at least, afferent nerve injury, and that the afferent
nerves are probably involved in the procedure and
its effects. Still, more work needs to be done to
tease apart the underlying mechanism of this effect
and the role of afferent renal nerves in the patho-
physiology of hypertension.
Such ground-breaking studies of this new ap-
proach for use in patients with resistant hyperten-
sion pave the way for future research in other pa-
tient populations. For instance, this technique might
be used to treat milder, but still resistant, forms of
hypertension or hypertension in patients with se-
vere kidney disease or renal artery stenosis. All
such patients were excluded from the recent stud-
ies. Catheter-based renal denervation might also
have applications for the treatment of other diseases
thought to be associated with excessive sympathetic
outflow, such as chronic kidney failure, cardiac fail-
ure and cirrhosis with ascites [5].
In summary, catheter-based renal sympathetic
denervation shows great promise as a safe and ef-
fective therapeutic technique for patients with hy-
pertension and, potentially, for other diseases
thought to be associated with renal sympathetic and
afferent overstimulation. To further elucidate the
potential clinical applications of this novel technique
in the setting of resistant hypertension, a larger
randomized controlled trial with more prolonged
and in-depth follow-up is planned, with results ex-
pected in the years to come.
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